Jump to navigation Jump to search
Note: Penpulimab is approved in China, but does not appear to have a brand name at this time.
Mechanism of action
Diseases for which it is used
History of changes in NPMA indication
- 8/5/2021: Approved for treatment of patients with relapsed or refractory (“r/r”) classic Hodgkin’s lymphoma (“cHL”) after at least second-line systemic chemotherapy treatment.
Also known as
- Code name: AK105